microdosing retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide, L-Theanine, The Science of

Novel GLP-1RAs improve efficacy and show promise beyond obesity such as addiction

The incidence is dose-dependent, meaning higher doses produce more nausea

Risk factors that increased the likelihood of developing NAION included a history of DR, insulin use, male sex, white race, dual eligibility in Medicare and Medicaid, rural residency, sleep apnea and concurrent use of amiodarone and GLP-1 agonists

however, the signalling cascade and downstream targets mediating this effect are not well established

Nine participants in the treatment group recorded at least one serious adverse event compared with 11 given placebo